Why your insurance might cover Wegovy and not Mounjaro (or vice versa)

A reader forwarded me a denial letter. Her US insurer had covered Wegovy without much fuss. They'd denied Mounjaro with a form letter. Same patient, same prior-authorization paperwork, same prescriber. The denial said something vague about preferred alternatives. She wanted to know why and what to do.

The why is the more interesting answer. The what-to-do is shorter.

Why first. Your insurance plan doesn't directly negotiate prices with Eli Lilly or Novo Nordisk. They contract with a pharmacy benefit manager, a PBM, who negotiates on their behalf. The three big PBMs in the US are CVS Caremark, Express Scripts, and OptumRx. They cover something like 80% of US prescription benefits between them. Each one has a formulary, which is the list of drugs they prefer in each category. Drugs on the formulary cost the patient less. Drugs not on the formulary cost the patient more, sometimes a lot more, sometimes nothing at all (which is what "denied" usually means in practice).

The PBM picks which drugs to put on the formulary based on which manufacturer offered the best rebate. Not the cheapest drug to the patient. The best rebate to the PBM. Sometimes those align. Often they don't.

For GLP-1s in 2026, the rebate game shakes out roughly like this. Caremark has had Novo Nordisk products preferred for several years. They tend to cover Wegovy and not Mounjaro. Express Scripts has historically tilted Lilly. OptumRx is more mixed and changes more often. The same patient, with the same medical situation, gets different answers depending on which PBM their employer's plan uses.

If your denial letter mentions "preferred alternatives," what it's actually saying is: the PBM gets a bigger rebate from the other manufacturer. The drug they're denying isn't medically inferior. It's just not on the contract this year.

Two things that follow from this.

First, your appeal might work. PBMs have an exception process. If your prescriber writes a letter saying you specifically need the drug they denied (because of a side effect on the alternative, an allergy, a documented therapeutic failure, or a clinical reason like why tirzepatide vs semaglutide matters for your particular profile), the appeal goes through. Not always. Often. The appeal process is a paperwork hassle, not a medical conversation, and most prescribers will write the letter if you ask. Some will groan first. Ask anyway.

Second, the formulary changes every year. Sometimes mid-year. The drug your insurance denies in May 2026 might be covered in January 2027 because the contract gets renegotiated. If your appeal fails this year and the medication is unaffordable as cash-pay, it's worth checking again at open enrollment. It's also worth knowing whether your employer offers more than one health plan, because they might have different PBMs with different formularies.

The other thing worth knowing: the manufacturer copay programs are real. Both Lilly and Novo offer copay-savings cards that can drop your monthly out-of-pocket meaningfully if your insurance covers the drug at all. They don't help if you're entirely uncovered (these programs require commercial insurance) but they can take a $200 monthly copay down to $25 for the medication that is on your formulary.

The cash-pay options are improving. Lilly launched LillyDirect with single-dose vials at lower cash pricing for patients without coverage. Novo has a similar pathway forming. Foundayo (the new oral GLP-1) launched at $149/month cash. The cash-pay landscape in 2026 is meaningfully better than it was even a year ago.

What I told the reader specifically: write the appeal. Don't take the first denial as final. Get your prescriber to write a clinical justification (mention any specific reason tirzepatide is preferred over semaglutide for you, like the dual mechanism, your A1c, comorbidities). If the appeal fails, look at your other plan options at open enrollment. If you're stuck with the formulary they have, the drug they covered (Wegovy) is genuinely good and the difference between Wegovy and Mounjaro for most people is smaller than the marketing suggests. Switching to the covered drug is reasonable. Paying $1000/month cash for a year because you didn't appeal is not.

The PBM contract layer is the most opaque part of US healthcare and the one nobody explains to patients. Knowing it exists changes how you read your denial letters. The denial isn't medical. It's contractual. Contracts can be appealed and contracts get renegotiated. Read the letter that way.